Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE | BSE: 532321
₹991.10
₹-20.60
(-2.04%)
As on 18-May-2026 15:54IST
Market cap
₹99,627 Cr
Revenue (TTM)
₹26,089 Cr
P/E Ratio
20.2
P/B Ratio
3.8
Div. Yield
1.1 %
Quality Score
9/10
Growth Score
8/10
Valuation Score
5/10
Momentum Score
5/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹4,938 Cr
-
ROE
21.1 %
-
ROCE
26.1 %
-
Industry P/E
31.55
-
EV/EBITDA
12.5
-
Debt to Equity
0.1
-
Book Value
₹261
-
EPS
₹51.5
-
Face value
1
-
Shares outstanding
1,006,233,990
10 Years Aggregate
CFO
₹26,398.10 Cr
EBITDA
₹35,164.10 Cr
Net Profit
₹23,180.90 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| 8.4 | 5.0 | 9.3 | 9.8 | 24.1 | 10.1 | 11.9 |
|
BSE Healthcare
| 8.9 | 8.8 | 9.5 | 11.4 | 27.0 | 14.4 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| -6.1 | 39.0 | 64.1 | -13.1 | 1.0 | 87.5 | -27.4 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
|
991.1 | 99,627.2 | 26,089.3 | 4,933.9 | 24.7 | 21 | 20.2 | 3.8 |
| 27,925.0 | 58,731.1 | 6,929.1 | 1,552.0 | 26.2 | 35.3 | 37.8 | 12.3 | |
| 5,468.0 | 64,749.2 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27.3 | 4.6 | |
| 1,500.5 | 86,479.3 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 24.8 | 2.4 | |
| 426.3 | 69,123.6 | 16,927.0 | 368.8 | 8.8 | -0.6 | 179.3 | 2.0 | |
| 2,389.8 | 40,357.6 | 3,821.7 | 1,036.0 | 32.5 | 51.4 | 39 | 17.8 | |
| 1,646.3 | 41,630.3 | 9,504.5 | 947.8 | 15.9 | 14.6 | 45.8 | 5.3 | |
| 2,252.4 | 1,02,503.2 | 27,958.0 | 5,355.5 | 26.6 | 27.4 | 19.2 | 4.6 | |
| 2,495.7 | 1,03,130.7 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 58 | 6.6 | |
| 1,905.8 | 4,55,129.9 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 41.7 | 5.6 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Who made the right move - FPI or MF?
4 min read•By Yash Rohra
5 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products... segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. Read more
-
Incorporated
1995
-
Chairman
Pankaj R Patel
-
Managing Director
Sharvil P Patel
-
Group
Cadila
-
Headquarters
Ahmedabad, Gujarat
-
Website
Looking for more details about Zydus Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Zydus Lifesciences
What is the current share price of Zydus Lifesciences Ltd Today?
The share price of Zydus Lifesciences Ltd is ₹991.10 (NSE) and ₹991.20 (BSE) as of 18-May-2026 15:54 IST. Zydus Lifesciences Ltd has given a return of 24.08% in the last 3 years.
What is the current PB & PE ratio of Zydus Lifesciences Ltd?
The P/E ratio of Zydus Lifesciences Ltd is 20.17 times as on 18-May-2026, a 36 discount to its peers’ median range of 31.55 times.
The P/B ratio of Zydus Lifesciences Ltd is 3.79 times as on 18-May-2026, a 18 discount to its peers’ median range of 4.63 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.69
|
3.72
|
|
2024
|
26.20
|
5.10
|
|
2023
|
25.37
|
2.84
|
|
2022
|
7.96
|
2.10
|
|
2021
|
21.16
|
3.47
|
What is the 52 Week High and Low of Zydus Lifesciences Ltd?
The 52-week high and low of Zydus Lifesciences Ltd are Rs 1,059.05 and Rs 835.50 as of 18-May-2026.
What is the market cap of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of ₹ 99,627 Cr as on 18-May-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Zydus Lifesciences Ltd?
Before investing in Zydus Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.